Geoffrey Maltzahn - Kaleido Biosciences President Co-Founder

KLDODelisted Stock  USD 0.01  0.00  0.00%   

President

Mr. Geoffrey von Maltzahn is the President, CoFounder of the Company. He is a leading innovator and entrepreneur in the microbiome and biotechnology and is a cofounder of companies that have achieved over 3 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has cofounded multiple biotech companies including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals . He recently served as the President of Indigo, where he led the creation of the worlds largest plant microbiome database and development of the companys first commercial products. Von Maltzahn is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiomebased technologies and was recognized with numerous awards, including the prestigious LemelsonMIT student prize, given to the most innovative student at MIT. Von Maltzahns innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his PhD from MIT in the HarvardMIT Division of Health Sciences and Technology.
Professional MarksPh.D
Phone617 674 9000
Webhttps://kaleido.com

Kaleido Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.9993) % which means that it has lost $0.9993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.8057) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences' management efficiency ratios could be used to measure how well Kaleido Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 5.55 M in liabilities with Debt to Equity (D/E) ratio of 2.05, implying the company greatly relies on financing operations through barrowing. Kaleido Biosciences has a current ratio of 1.39, which is within standard range for the sector. Debt can assist Kaleido Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kaleido Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kaleido Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kaleido to invest in growth at high rates of return. When we think about Kaleido Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Thomas CorrTootsie Roll Industries
69
Steven BurdetteHaverty Furniture Companies
62
Richard HareHaverty Furniture Companies
57
Kathleen DalyJenningsHaverty Furniture Companies
53
Ann ZaccariaBassett Furniture Industries
N/A
Rawson HavertyHaverty Furniture Companies
67
Chris KellyLGI Homes
N/A
John DanielBassett Furniture Industries
56
David BakerBassett Furniture Industries
63
Allan DeNiroHaverty Furniture Companies
64
Gary KniselyHanover Foods
75
Thomas CurranHaverty Furniture Companies
60
Peitro GiraffaHanover Foods
62
Andrew MathiasSL Green Realty
50
John MajorsTootsie Roll Industries
55
Janet TaylorHaverty Furniture Companies
62
Moina BanerjeeJBG SMITH Properties
36
Parimala RaoSL Green Realty
N/A
Helen BautistaHaverty Furniture Companies
57
Rachel EatonLGI Homes
42
David PaulJBG SMITH Properties
61
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 76 people. Kaleido Biosciences [KLDO] is a Pink Sheet which is traded between brokers as part of OTC trading. Kaleido Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Kaleido Biosciences Leadership Team

Elected by the shareholders, the Kaleido Biosciences' board of directors comprises two types of representatives: Kaleido Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kaleido. The board's role is to monitor Kaleido Biosciences' management team and ensure that shareholders' interests are well served. Kaleido Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kaleido Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geoffrey Maltzahn, President Co-Founder
Jeremy Buzzard, Senior Vice President - Corporate Development
Johannes Vlieg, Chief Scientific Officer
Grady Burnett, Director
Mark Wingertzahn, VP Devel
Bonnie Bassler, Director
Jeffery Moore, Senior Vice President - Finance & Administration
Clare Fisher, Chief Business Officer
LLM JD, Chief Advisor
Jerald Korn, General Counsel, Corporate Secretary
Mike Bonney, Chairman of the Board, CEO
John Sculley, Director
Ruth ThieroffEkerdt, Chief Medical Officer
Theo MelasKyriazi, Independent Director
Kimberly Hocknell, VP Operations

Kaleido Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kaleido Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kaleido Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kaleido Biosciences' short interest history, or implied volatility extrapolated from Kaleido Biosciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Kaleido Pink Sheet

If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format